Daily Aspirin Treatment After Preeclampsia

This study is looking at whether taking a daily low-dose aspirin (162mg) after experiencing preeclampsia can help prevent lasting blood vessel damage. Preeclampsia is a serious condition during pregnancy that can increase a woman's risk of heart disease later in life. Researchers want to see if aspirin can improve how your blood vessels work. You may be able to join if you are a woman between 18 and 50 years old and had preeclampsia within the last five years. The study will measure changes in your blood vessel function to see if aspirin is effective. The current status of this study is unclear.

Study design
This study is comparing daily aspirin (162mg) to a placebo (an inactive pill) in 40 women. It is an interventional study, meaning participants will receive a specific treatment.
What's involved
The study will measure your blood vessel function at the beginning and again after 12 weeks. Specific details about visits or other procedures are not provided.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 weeks after starting treatment to measure blood vessel function.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06168461

Daily Aspirin Treatment After Preeclampsia

Recruiting
EARLY_PHASE1Ages 18–50InterventionalBasic science
Anna Stanhewicz, PhD
~40 participants
Updated 2025-12-15 on ClinicalTrials.gov
What's tested:AspirinPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
magnitude of microvascular endothelial function
Measured over baseline, 12 weeks
+2 more outcomes measured
Preeclampsia
1 sites across 1 states
Iowa1

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

had preeclampsia in the past 5 years,
18 years or older

Exclusion

current daily aspirin use,
skin diseases,
current tobacco or nicotine use (including vaping),
diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2,
statin or other cholesterol-lowering medication,
current antihypertensive medication,
history of hypertension prior to pregnancy,
history of gestational diabetes,
currently pregnancy,
body mass index \<18.5 kg/m2,
allergy to materials used during the experiment.(e.g. latex),
known allergies to study drugs,
bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).
  • magnitude of microvascular endothelial functionbaseline, 12 weeks

    skin blood flow response to acetylcholine delivered via intradermal microdialysis

  • magnitude of brachial artery endothelial functionbaseline, 12 weeks

    brachial artery flow mediated dilation

  • magnitude of microvascular endothelin-1 mediated constrictionbaseline, 12 weeks

    skin blood flow response to endothelin-1 delivered via intradermal microdialysis